https://www.selleckchem.com/pr....oducts/vps34-inhibit
ated metastatic patients. A significant improvement in terms of progression-free survival and OS was observed rendering this drug a potential novel standard in this patient population.A Mn(II)/bipyridine-catalyzed bromination reaction of unactivated aliphatic C(sp3)-H bonds has been developed using N-bromosuccinimide (NBS) as the brominating reagent. The reaction proceeded in moderate-to-good yield, even on a gram scale. The introduced bromine atom can be converted into fluorine and allyl groups.The kinetics of enzymatic desym
Curtir
Comentario
Compartilhar
